Ronny Hermansen, CEO of Genetic Analysis, comments:
“The third quarter was marked by consistent progress across Genetic Analysis’ commercial and development activities, underscoring continued execution on our long-term growth strategy. The third quarter was influenced by the slower summer holiday period, but sales were slightly higher than last year.”

Q3 2025 (01.07.2025 – 30.09.2025)

• Operating income amounted to NOK 3.2 million (3.6)
• Sales revenue amounted to NOK 2.1 million (2.0)
• Net profit/loss amounted to NOK -3.3 million (-3.2)
• EBITDA amounted to NOK -1.8 million (-1.8)
• Total assets amounted to NOK 43.8 million (41.6)
• Equity ratio amounted to 67% (56%)
• Earnings per share amounted to NOK -0,05 (-0,07)

First nine months 2025 (01.01.2025 – 30.09.2025)

• Operating income amounted to NOK 14.3 million (13.3)
• Sales revenue amounted to NOK 10.4 million (9.7)
• Net profit/loss amounted to NOK -8.8 million (-13.8)
• EBITDA amounted to NOK-4.5 million (-9.4)
• Total assets amounted to NOK 43.8 million (41.6)
• Equity ratio amounted to 67% (56%)
• Earnings per share amounted to NOK -0,14 (-0,31)

Important insights

• Sales revenue reached NOK 2.1 million in Q3, up 2.9% from last year and up 6.1% in constant currency. EBITDA was NOK    -1.8 million in Q3, in line with Q3 last year.
• During the quarter, our development team completed the development phase of the new IBD Dx marker project, and in November we communicated that the project will be transferred into the validation phase.
• The relative share of sales to the US was high in Q3, and this combined with the new US imports taxes took the Gross Margin down from 76% in Q3 2024 to 64% this quarter.
• Our service lab partner in the US, Pangea Lab, has completed the set-up and training to run the GA-map® MHI GutHealth test and is thus ready to serve customers in the US.

Financial highlights

• Total operating income ended at NOK 3.2 million in Q3 2025 (NOK 3.6 million).
• Sales revenues in Q3 2025 reached NOK 2.1 million with a 2.9% increase compared to the corresponding quarter in 2024 (NOK 2.0 million). At constant currencies, the sales increase was 6.1%.
• Gross margin decreased to 64% in Q3 2025 compared to 76% for the same period last year. The decrease is an effect of import duties to the US. If adjusted for US import duties, GM would have been 75%.
• EBITDA of NOK -1.8 million compared to NOK –1.8 million in the corresponding quarter of 2024.
• Net loss was NOK -3.3 million compared to NOK -3.2 million in the corresponding quarter of 2024.
• Q3 2025 results were negatively impacted by US import duties. This was partly offset by lower operating cost spending.

Significant events during and after Q3 2025

• On July 29, Genetic Analysis AS and Pangea Laboratory LLC announced the launch of the GA-map® MHI GutHealth as a Research Use Only (RUO) test in the U.S. Developed in collaboration with Ferring Pharmaceuticals, the test provides actionable insights into antibiotic-induced microbiome imbalances and will initially target patients with recurrent Clostridioides difficile infection (rCDI). The analysis will be performed at Pangea’s CLIA-certified and CAP-accredited laboratory in Tustin, California.
• On September 24, Genetic Analysis AS announced the global launch of the GA-map® MHI GutHealth reagent kit for Luminex xMAP® users. The test, developed in collaboration with Ferring Pharmaceuticals, provides an advanced tool for measuring antibiotic-induced microbiome imbalances, validated for recurrent Clostridioides difficile infection (rCDI). The kit expands GA’s product portfolio into a new diagnostic field and strengthens its position in standardized microbiome testing worldwide.
• July 29-31, the GA commercial team attended one of the worlds’ largest diagnostics and laboratory medicine congress, ADLM in Chicago. The venue was used to showcase the novel GA-map® MHI GutHealth test, reaching a broad audience, primarily laboratories and clinicians from the USA.
• November 17, Genetic Analysis AS announced that the IBD Precision Dx project has now progressed into the final validation phase and the completion of software development, following the successful completion of the biomarker panel development.

For further information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com

This disclosure contains information that Genetic Analysis AS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, at the time indicated by Genetic Analysis AS news distributor upon publication of this press release.